Compass Therapeutics
CMPX
78 hedge funds and large institutions have $187M invested in Compass Therapeutics in 2024 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 35 reducing their positions, and 8 closing their positions.
208% more capital inflows, than outflows
Capital inflows: $22.4M | Capital outflows: $7.27M
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
1% more funds holding
Funds holding: 77 → 78 (+1)
1.18% more ownership
Funds ownership: 67.54% → 68.72% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
49% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cormorant Asset Management
Boston,
Massachusetts
|
+$9.6M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$5.48M |
| 3 |
MPM BioImpact
Boston,
Massachusetts
|
+$3.41M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.16M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$554K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$2.5M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$1.3M |
| 3 |
Millennium Management
New York
|
-$519K |
| 4 |
Braidwell
Stamford,
Connecticut
|
-$496K |
| 5 |
Element Capital Management
New York
|
-$458K |
CMPX Hedge Fund Activity: Q1 2024 in Review
78 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q1 2024, worth a combined $187M — up 39% from $134M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CMPX positions and 8 closed out — a net gain of 1 holder — while 18 added to existing stakes and 35 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $9.6M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $2.5M sold.
- 78 institutional investors held Compass Therapeutics (CMPX) as of Q1 2024, up from 77 in Q4 2023.
- Funds reported $187M of Compass Therapeutics stock for Q1 2024, up 39% quarter-over-quarter.
- 9 funds opened new Compass Therapeutics positions in Q1 2024 and 8 closed out, a net change of +1 holder.
- The largest Compass Therapeutics buyer in Q1 2024 was Cormorant Asset Management, an estimated $9.6M added.
- The largest Compass Therapeutics seller in Q1 2024 was Avidity Partners Management, an estimated $2.5M sold.
Based on aggregated 13F filings for Q1 2024.